Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Mobile Health Policy Proposal Draws Fire From Far And Wide

This article was originally published in The Pink Sheet Daily

Executive Summary

A draft guidance meant to clarify FDA's regulatory policies surrounding mobile medical applications has raised as many questions as it tried to answer.

You may also be interested in...



A Successful Pharma Mobile Strategy Means Matching The Right Info To The Right Device

Pfizer and Sanofi representatives discuss how pharmaceutical firms can best leverage mobile platforms to reach consumers. Elements to consider include ensuring a mobile website makes a good first impression, delivering a message that is simple and on-point, integrating the mobile platform strategy with the brand strategy and considering how best to use tools like text messaging and apps.

FDA Wants Mobile App Guidance To Connect With Device-Reg-Naïve Developers

Pending FDA guidance on mobile medical applications will be of most value in reaching out to those software developers who have not yet worked within the medical device industry, CDRH policy advisor Bakul Patel emphasized last week.

Industry Applauds FDA Draft Guidance On Mobile Medical Apps

The medical device and software industries voiced support last week for a July 19 FDA draft guidance that helps clarify the types of mobile software applications that would face FDA regulation.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS072963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel